Compare EXPI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | KALV |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 2014 |
| Metric | EXPI | KALV |
|---|---|---|
| Price | $6.72 | $20.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.75 | ★ $32.60 |
| AVG Volume (30 Days) | 875.3K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-09-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,147,681.00 | $50,000,000.00 |
| Revenue This Year | $6.26 | $187.19 |
| Revenue Next Year | $5.50 | $54.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 220.39 | ★ 495.66 |
| 52 Week Low | $5.66 | $9.83 |
| 52 Week High | $12.23 | $21.31 |
| Indicator | EXPI | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 61.63 |
| Support Level | $5.68 | $14.66 |
| Resistance Level | $11.36 | $21.31 |
| Average True Range (ATR) | 0.23 | 1.22 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 98.07 | 83.59 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.